DURECT (NASDAQ:DRRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

DURECT Price Performance

Shares of NASDAQ:DRRX opened at $0.80 on Thursday. The company has a market capitalization of $24.83 million, a P/E ratio of -1.31 and a beta of 0.91. The business’s 50 day simple moving average is $0.80 and its 200 day simple moving average is $1.00. DURECT has a 1 year low of $0.70 and a 1 year high of $1.88.

DURECT (NASDAQ:DRRX) last announced its quarterly earnings results on Wednesday, March 26th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.12). DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%. The firm had revenue of $2.30 million during the quarter, compared to the consensus estimate of $6.91 million. On average, sell-side analysts anticipate that DURECT will post -0.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Richmond Brothers Inc. raised its holdings in shares of DURECT by 12.2% in the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after acquiring an additional 138,920 shares during the last quarter. Jane Street Group LLC boosted its stake in DURECT by 266.0% during the 4th quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares in the last quarter. 28.03% of the stock is owned by institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.